CA-GLOBALLOGIC-INC.
9.11.2021 12:02:05 CET | Business Wire | Press release
GlobalLogic Inc. ,1 a Hitachi Group company and leader in Digital Engineering, today announced the availability of its enhanced Microservices Accelerator, a comprehensive and pluggable digital microservices development platform. Developed by GlobalLogic, this technology is used in conjunction with the company’s Digital Engineering services to greatly simplify and accelerate the design, configuration, and deployment of Microservices platforms – which are the most commonly deployed architectures in creating new digital experiences.
Notably, the Microservices Accelerator is currently the foundation platform for many GlobalLogic clients including EyeCare Partners , the leading healthcare service provider for optometry and ophthalmology; Petplan , the most comprehensive pet health care insurance in North America; and DISA Global Solutions , the leading provider of safety, compliance, and screening services.
Part of GlobalLogic’s Digital Accelerators product offerings, the Microservices Accelerator provides a complete solution that includes a project configurator and a set of pluggable modules that perform the most common Non-Functional Requirements (NFRs) required by any microservices-based deployment. The latest release introduces advanced capabilities including CloudEvents support, security framework upgrades, and ETag support to enhance caching capabilities.
Digital Accelerator Key Value Proposition
Driving the accelerator’s development were Independent Software Vendors (ISVs), enterprises, and startup company needs. As more companies move their product offerings to cloud-native platforms, developers seek codified tools that can efficiently address and automate common, time-consuming processes. Early results have shown a savings of up to 75 person months for a typical large-size deployment project, which means significantly reduced time to market, a more reliable and repeatable process, and increased ROI.
“Having deployed many such platforms over the last couple of years, GlobalLogic has established a strong body of knowledge that we have included in this toolset — ranging from enterprise-scale capabilities to best practices. Our clients are already shaving off months from the bootstrap, and reducing overall implementation costs and effort with our solution,” said Piyush Jha , SVP & Chief of Technology and Strategy (APAC), GlobalLogic.
“Microservices is a great architectural paradigm that takes modularity to the next level and, in many ways, is fundamental for achieving the massive scale requirements of modern software,” said Deepak Gupta , SVP & Global Head of Technology Practices, GlobalLogic. “This accelerator is an out-of-box solution that allows engineers to set up complex architectures in a single day, rather than the months typically required. Moreover, it provides a required guardrail to operate within, and reduces the possibilities of human error — which is essential to being successful with this programming paradigm.”
Inter-Company Deployment
As part of Hitachi’s acquisition of GlobalLogic, the accelerator technology will be utilized in Hitachi's services and solutions going forward.
“Hitachi Application Services Division is excited to leverage the GlobalLogic Accelerators in its service delivery schema,” said Emi Goto, Senior Director, Application Services Division, Hitachi, Ltd. “The growth of our Lumada business will be accelerated in the expanding Digital Transformation market by combining the innovativeness of GlobalLogic's Experience Design and Chip-to-Cloud software engineering with Hitachi's enterprise application delivery experiences in mission critical systems.”
GlobalLogic’s Microservices Accelerator supports both containers and functions as a service-based deployment model across cloud hyperscalers Microsoft Azure, AWS, and Google Cloud Platform (GCP).
About GlobalLogic
GlobalLogic (www.globallogic.com ) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company.
GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.
1 July 14, 2021 News Release "Hitachi Completes Acquisition of GlobalLogic” https://www.hitachi.com/New/cnews/month/2021/07/f_210714.pdf
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005358/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom